Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain, Epilepsy, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA2D1 (alpha-2/delta-1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA2D1 ECD-Fc Fusion Protein (Human, Mouse, Cyno orthologs). High purity (>95%), Endotoxin <1EU/µg. HEK293 Expressed (Native Glycosylation). | View CACNA2D1 Products |
| Gene Delivery | CACNA2D1 Lentivirus Premade Particles (Full-length ORF, codon-optimized). For stable cell line construction preserving native membrane topology. | View CACNA2D1 Products |
| Benchmark Ab | Anti-CACNA2D1 Reference Antibody (Recombinant human IgG1, Sequence Verified). | View CACNA2D1 Products |
| Validator | CACNA2D1 siRNA Set (Three unique target sequences for knockdown verification). | View CACNA2D1 Products |
| Selectivity Control (CACNA2D2) | CACNA2D2 ECD Protein. For off-target liability screening (CNS toxicity assessment). | View CACNA2D2 Products |
| Selectivity Control (CACNA2D3) | CACNA2D3 ECD Protein. Subfamily selectivity panel member for safety profiling. | View CACNA2D3 Products |
| Functional Partner | CACNA1A (Cav2.1) Channel Protein. Pore-forming alpha-1 subunit for co-expression functional assays. | View CACNA1A Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity vs CACNA2D2/3 | Homolog panel proteins strictly verified by mass spec; >95% purity. |
| Native Conformation & Membrane Topology | Lentivirus-based stable cell lines preserving native glycosylation and proper membrane insertion for flow cytometry. |
| Cross-Species Translation (Human/Mouse/Cyno) | Ortholog panel with >95% sequence coverage; HEK293 expressed for consistent glycosylation. |
| Gabapentin Binding Site Competition Mapping | Mutant CACNA2D1 proteins (R217A, R218A variants) for epitope binning and mechanism studies. |
| Internalization Potential (ADC Development) | High-purity ECD-Fc for pH-dependent internalization assays; Lentivirus-expressed full-length for live-cell imaging. |
| Assay Specificity & False Positives | Validated siRNA included for knockdown verification and target specificity confirmation. |
Live CACNA2D1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CACNA2D1 is defined by the success of first-generation gabapentinoids (pregabalin and gabapentin) for neuropathic pain and epilepsy. However, the field is rapidly evolving toward next-generation ligands with improved subtype selectivity, peripherally restricted modulators, and biologic modalities such as monoclonal antibodies and ADCs. In oncology, emerging evidence of CACNA2D1's role in cancer stem cell markers and tumor metastasis is opening new indications for ADC and CAR-T strategies. The next 3-5 years will focus on overcoming drug resistance mutations in the gabapentin-binding pocket (e.g., R217A, R218A) and developing combination therapies with Nav1.7 blockers or checkpoint inhibitors. Regulators and clinicians demand fewer central nervous system side effects, driving R&D toward highly selective CACNA2D1 modulators and antibodies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-gen Small Molecule | Pfizer, Daiichi Sankyo, Biogen, Vertex | Neuropathic Pain, Fibromyalgia, Epilepsy | Paralog selectivity binding assays; Mutant proteins for resistance screening (R217A/R218A). |
| Monoclonal Antibody | Regeneron, Academic Consortia | Chronic Peripheral Pain, Fibrosis | Cell-based binding assay (Lentivirus stable line required); Cross-species reactivity panel. |
| ADC | Emerging Biotech | Solid Tumors (Breast, Prostate, Gastric, Liver) | Internalization assay (pH-sensitive dyes); Tumor vs Normal selectivity screening. |
| Bispecific (CACNA2D1 x Nav1.7) | Preclinical Startups | Severe Pain Syndromes | Co-expression stable cell lines; Heterodimer validation. |
| Ion Channel Complex Modulators | Multiple academic & biotech consortia | Refractory Chronic Pain, Fibromyalgia | Cell surface trafficking assays (Need stable lentivirus lines for flow cytometry). |